Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.7 (1y: +35%)
Market Cap 125.78 M P/E(ttm)
Enterprise Value 97.71 M P/B 3.50
INO- AMEX (USA)
Inovio Pharmaceuticals, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$0.70
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. INO: No Debt )
INO' s 10-Year Cash to Debt Range
Min: 1.17   Max: No Debt
Current: No Debt
Equity to Asset 0.761
INO's Equity to Asset is ranked higher than
82% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. INO: 0.761 )
INO' s 10-Year Equity to Asset Range
Min: 0.49   Max: 0.93
Current: 0.76
0.49
0.93
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INO: No Debt )
INO' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
Z-Score: -2.8
M-Score: 0.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -570.40
INO's Operating margin (%) is ranked lower than
54% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. INO: -570.40 )
INO' s 10-Year Operating margin (%) Range
Min: -8188.9   Max: -83.1
Current: -570.4
-8188.9
-83.1
Net-margin (%) -477.5
INO's Net-margin (%) is ranked lower than
53% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. INO: -477.5 )
INO' s 10-Year Net-margin (%) Range
Min: -5759.3   Max: -79.5
Current: -477.5
-5759.3
-79.5
ROE (%) -57.3
INO's ROE (%) is ranked higher than
50% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INO: -57.3 )
INO' s 10-Year ROE (%) Range
Min: -160.1   Max: -31
Current: -57.3
-160.1
-31
ROA (%) -43.6
INO's ROA (%) is ranked lower than
51% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. INO: -43.6 )
INO' s 10-Year ROA (%) Range
Min: -110.1   Max: -25
Current: -43.6
-110.1
-25
Revenue Growth (%) -29.3
INO's Revenue Growth (%) is ranked lower than
57% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INO: -29.3 )
INO' s 10-Year Revenue Growth (%) Range
Min: -67.7   Max: 95.1
Current: -29.3
-67.7
95.1
EPS Growth (%) -19.3
INO's EPS Growth (%) is ranked lower than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INO: -19.3 )
INO' s 10-Year EPS Growth (%) Range
Min: -31.8   Max: 23.4
Current: -19.3
-31.8
23.4
» INO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

INO Guru Trades in Q2 2012

Jim Simons 123,800 sh (+548.17%)
» More
Q3 2012

INO Guru Trades in Q3 2012

Jim Simons 191,500 sh (+54.68%)
» More
Q4 2012

INO Guru Trades in Q4 2012

Jim Simons 175,300 sh (-8.46%)
» More
Q1 2013

INO Guru Trades in Q1 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 3.50
INO's P/B is ranked higher than
69% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. INO: 3.50 )
INO' s 10-Year P/B Range
Min: 0.38   Max: 20.85
Current: 3.5
0.38
20.85
P/S 25.38
INO's P/S is ranked higher than
54% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. INO: 25.38 )
INO' s 10-Year P/S Range
Min: 1.51   Max: 732
Current: 25.38
1.51
732
PFCF 5.30
INO's PFCF is ranked lower than
100% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. INO: 5.30 )
INO' s 10-Year PFCF Range
Min: 2.5   Max: 128
Current: 5.3
2.5
128
EV-to-EBIT 0.3
INO's EV-to-EBIT is ranked higher than
95% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. INO: 0.3 )
INO' s 10-Year EV-to-EBIT Range
Min: 349.7   Max: 5578.8
Current: 0.3
349.7
5578.8

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 35
INO's Price/Net Cash is ranked lower than
53% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 8.90 vs. INO: 35 )
INO' s 10-Year Price/Net Cash Range
Min: 2.1   Max: 25
Current: 35
2.1
25
Price/Tangible Book 7.8
INO's Price/Tangible Book is ranked higher than
61% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. INO: 7.8 )
INO' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 12.9
Current: 7.8
1.9
12.9
Price/Median PS Value 2
INO's Price/Median PS Value is ranked lower than
51% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. INO: 2 )
INO' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 4.7
Current: 2
0.4
4.7
Forward Rate of Return (Yacktman) -35.91
INO's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INO: -35.91 )
INO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.2   Max: -6.5
Current: -35.91
-13.2
-6.5

Business Description

Inovio Biomedical Corporation was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The company is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. Its SynCon technology enables the design of 'universal' vaccines capable of providing cross-protection against existing or changing strains of pathogens such as influenza and HIV. Its' electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Initial human data has shown this method can safely and significantly increase gene expression and immune responses. The company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus ('HCV') and human immunodeficiency virus ('HIV') vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative ('PATH/'MVI'), Nationa
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:GBMA.Germany
» More Articles for INO

Headlines

Articles On GuruFocus.com
comment on INO May 10 2013 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Any opinions regarding Apr 12 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK